Oragenics: It’s even worse than it looks!

Oragenics Positive Sentiment Signals

An evaluation of the rate of change in sentiment and the intensity of discussion reveals the following pictureDuring the past month, investor sentiment increasingly improved. Therefore, we rate this item as “Buy”. Let’s look at the intensity of discussions from last month. This provides information on whether a stock tends to receive a lot or little attention. The company was discussed more than usual and received increasing attention from investors. This leads to a “buy” rating. As a result, Oragenics’ stock receives a “buy” rating.

At what level is the P/E ratio?

With a price-earnings ratio (P/E) of 0.58, Oragenics’ stock is valued 99 percent lower than comparable companies in the “Biotechnology” sector (67.76), based on today’s quotes. This ratio in turn signals an undervaluation. This results in a “buy” rating from the perspective of fundamental analysis.

Price return currently not a buy recommendation

The share has generated a return of -56.61 percent in the past year. Compared to stocks in the same sector (“health care”), Oragenics is 82.42 percent below average (25.82 percent). The average annual return for securities from the same sector “biotechnology” is 26.23 percent. Oragenics is currently 82.84 percent below this figure. Due to the underperformance, we rate the stock an overall “Sell” at this level.

Too much of a good thing – the stock is overbought

A well-known means from technical analysis to assess whether a stock is currently “overbought” or “oversold” is the Relative Strength Index (RSI). This puts price movements over time in relation to each other. We look at the RSI on a 7-day and 25-day basis for Oragenics. Let’s start with the 7-day RSI, which is currently 75 points. This means that Oragenics is currently overbought. Thus, the stock is rated as a “Sell”. What about the 25-day RSI? In contrast to the RSI of the last 7 trading days, Oragenics is neither overbought nor -sold on this basis. The thus deviating rating of the stock for the 25-day RSI is therefore a “Hold” rating. Oragenics is thus given a bottom-line “Sell” rating for this point in our analysis.

Dimmed Chart Picture

The moving average price of Oragenics now stands at $0.31. The share itself has reached a price of 0.19 USD. The distance to the GD200 is thus -38.71 percent, leading to a “Sell” rating. In contrast, the GD50 for the past 50 days currently has a level of 0.22 USD. Thus, with a distance of -13.64 percent, the stock is a “Sell” from this perspective. Thus, we assign an overall rating of “Sell.”